 |
0 Diseases |  |
123 Trials |
|
123 Trials |  |
2738 News |  |
| «12...910111213141516171819...4142» |
- | anastrozole / Generic mfg., fulvestrant / Generic mfg.
Trial completion date, Surgery: Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. (clinicaltrials.gov) - Jun 13, 2022
P2, N=42, Active, not recruiting, Sponsor: University of Kansas Medical Center
Trial completion date: May 2022 --> May 2023
- | letrozole / Generic mfg., anastrozole / Generic mfg., tamoxifen / Generic mfg.
Journal: Adherence to Hormonal Therapy in Breast Cancer Patients in Saudi Arabia: A Single-Center Study. (Pubmed Central) - Jun 10, 2022
Disease progression and mortality were not found to be significantly associated with hormonal therapy adherence in this study. A larger study is required to confirm the findings of our study.
- | Epidaza (chidamide) / Chipscreen
New P2 trial, Metastases: Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. (clinicaltrials.gov) - Jun 8, 2022
P2, N=73, Not yet recruiting, Sponsor: wang shusen
- || Journal, Adverse drug reaction: Doping with aromatase inhibitors and oestrogen receptor modulators in steroid users: Analysis of a forum to identify dosages, durations and adverse drug reactions. (Pubmed Central) - Jun 8, 2022
A larger study is required to confirm the findings of our study. Patient narratives posted on forums can be a useful tool in the context of doping, to better understand practices, motivations and possibly to bring up pharmacovigilance signals.
- || anastrozole / Generic mfg.
PK/PD data, Journal: Evaluation of Pharmacokinetics and Safety With Bioequivalence of Anastrozole in Healthy Chinese Volunteers: Bioequivalence Study Findings. (Pubmed Central) - Jun 4, 2022
The severity of observed adverse events assessed according to the Common Terminology Criteria for Adverse Events (version CTCAE4.03) was mild, and some of the adverse events were not caused by anastrozole. Furthermore, the results of our study under fasting and fed conditions demonstrated bioequivalence of the test and reference products.
- || anastrozole / Generic mfg.
TBT do maior congresso de urologia do mundo, #AUA2022 em New Orleans - EUA. Na oportunidade a Presidente do XV Congresso Sul Brasileiro de Urologia, Dra. Karin Anzolch, pode acompanhar as inovações, pesquisas e novas tecnologias juntamente com os experts na especialidade (Twitter) - Jun 2, 2022
- | denifanstat (TVB-2640) / Sagimet Biosci
Trial completion date, Trial primary completion date: TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Jun 1, 2022
P2, N=80, Recruiting, Sponsor: Mayo Clinic
Furthermore, the results of our study under fasting and fed conditions demonstrated bioequivalence of the test and reference products. Trial completion date: Jul 2022 --> Jul 2024 | Trial primary completion date: Jul 2022 --> Jul 2023
- | letrozole / Generic mfg., anastrozole / Generic mfg.
Trial completion date, Trial primary completion date: Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer (clinicaltrials.gov) - Jun 1, 2022
P2, N=29, Recruiting, Sponsor: Mayo Clinic
Trial completion date: Jul 2022 --> Jul 2024 | Trial primary completion date: Jul 2022 --> Jul 2023 Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2022 --> Jun 2023
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal: Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment. (Pubmed Central) - May 30, 2022
The inter-day precision ranged from 1.6% to 14.9%, with accuracy between -14.3% and 14.6%, which is in accordance with the EMA and ICH guidelines on bioanalytical method validation. The method was successfully applied to samples from patients treated for HR+, HER2- breast cancer.
- |||| Ibrance (palbociclib) / Pfizer
Enrollment open, Trial initiation date, Circulating tumor DNA: TRAK-ER: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (clinicaltrials.gov) - May 26, 2022
P2, N=1100, Recruiting, Sponsor: Royal Marsden NHS Foundation Trust
The method was successfully applied to samples from patients treated for HR+, HER2- breast cancer. Not yet recruiting --> Recruiting | Initiation date: Sep 2021 --> Mar 2022
- ||| Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - May 24, 2022
P3, N=672, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Sep 2021 --> Mar 2022 Trial completion date: Jun 2022 --> Sep 2022
- ||||| NN1213 / Novo Nordisk
Enrollment closed: GIM10-CONSENT: CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer (clinicaltrials.gov) - May 24, 2022
P3, N=1000, Active, not recruiting, Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Trial completion date: Jun 2022 --> Sep 2022 Recruiting --> Active, not recruiting
- | anastrozole / Generic mfg.
Journal: Anastrozole-related dermatitis with mainly unilateral distribution. (Pubmed Central) - May 20, 2022
Recruiting --> Active, not recruiting No abstract available
- || Clinical, Review, Journal: Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer. (Pubmed Central) - May 19, 2022
In the past decade, the introduction of molecularly targeted agents against intracellular targets such as mammalian target of rapamycin (everolimus), cyclin-dependent kinases 4 and 6 (palbociclib, ribociclib, and abemaciclib), and phosphatidylinositol 3-kinase (alpelisib) has offered patients effective nonchemotherapy-based options, which are improving outcomes...Still, formatting a plan for these patients includes taking into account traditional prognostic factors such as menopausal status, previous treatments, disease-free interval for those patients with early breast cancer that has recurred, and tumor burden. To assist in developing this treatment plan, we will review the current data with systemic agents in the management of these patients.
- | anastrozole / Generic mfg.
Journal: A Case of Late Recurrence of Breast Cancer Causing Carcinomatous Pleurisy 29 Years Postoperatively (Pubmed Central) - May 18, 2022
In view of the patient's age, we initiated treatment by anastrozole...She continued to be treated with the endocrine therapy over 4.5 years. The late recurrence of breast cancer in the form of carcinomatous pleurisy 29 years postoperatively is rare.
- | Verzenio (abemaciclib) / Eli Lilly
Journal: A Case of Postoperative Pulmonary Metastasis of Breast Cancer with Complete Response by Abemaciclib plus Fulvestrant Therapy (Pubmed Central) - May 18, 2022
She received postoperative adjuvant therapy with oral anastrozole(ANA)for 5 years...However, the first CDK4/6 inhibitor, palbociclib, caused severe myelosuppression even when the dose was reduced by 2 levels...In June 2019, new multiple lung metastases appeared, and the patient was switched from ANA to fulvestrant, after which complete response was achieved in 6 months. CT in June 2021 showed no recurrence, and the patient(now 80-year-old)continues to take abemaciclib plus fulvestrant therapy.
- | anastrozole / Generic mfg.
@sbuoficial @AnzolchK @KAnzolch Encerramento do SBU-SP in situ #AUA22 (Twitter) - May 18, 2022
- ||| LOXO-783 / Eli Lilly
Enrollment open, Combination therapy, Monotherapy, Metastases: PIKASSO-01: A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (clinicaltrials.gov) - May 15, 2022
P1, N=260, Recruiting, Sponsor: Eli Lilly and Company
CT in June 2021 showed no recurrence, and the patient(now 80-year-old)continues to take abemaciclib plus fulvestrant therapy. Not yet recruiting --> Recruiting
- | Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial primary completion date, Metastases: AMBRE: Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (clinicaltrials.gov) - May 12, 2022
P3, N=378, Recruiting, Sponsor: UNICANCER
Not yet recruiting --> Recruiting Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Dec 2022 --> Dec 2024
- || Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of Abemaciclib in Indian Women With Advanced Breast Cancer (clinicaltrials.gov) - May 11, 2022
P4, N=200, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Dec 2022 --> Dec 2024 Trial completion date: Aug 2022 --> Mar 2023 | Trial primary completion date: Aug 2022 --> Mar 2023
- || amcenestrant (SAR439859) / Sanofi
Trial completion date, Monotherapy, Metastases: AMEERA-3: Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (clinicaltrials.gov) - May 4, 2022
P2, N=367, Active, not recruiting, Sponsor: Sanofi
Trial completion date: Aug 2022 --> Mar 2023 | Trial primary completion date: Aug 2022 --> Mar 2023 Trial completion date: Nov 2025 --> Sep 2023
- | Trial completion date, Combination therapy, Metastases: BOLERO-5: A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor (clinicaltrials.gov) - May 3, 2022
P2, N=159, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Nov 2025 --> Sep 2023 Trial completion date: Apr 2022 --> Nov 2022
- || Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (clinicaltrials.gov) - May 3, 2022
P2, N=327, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Apr 2022 --> Nov 2022 Trial completion date: Dec 2023 --> Dec 2024
- |||| anastrozole / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
@stolaney1 presents the results from the safety run-in of #Checkmate7A8 Neoadjuvant nivo/palbo/anastrozole resulted in promising efficacy, but 2/21 DLTs & several treatment discontinuations. Despite preclinical data suggesting synergy, CDK4/6i & IO appear challenging to combine. (Twitter) - May 3, 2022
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients (clinicaltrials.gov) - May 2, 2022
P=N/A, N=90, Recruiting, Sponsor: University of Maryland, Baltimore
Trial completion date: Dec 2023 --> Dec 2024 Trial completion date: Mar 2022 --> Mar 2025 | Trial primary completion date: Mar 2022 --> Mar 2024
- Ethnic/racial disparities in endocrine therapy compliance following intra-operative electronic brachytherapy for treatment of early-stage breast cancer () - Apr 29, 2022 - Abstract #ASBrS2022ASBrS_444;
P=N/A
African American and Caucasian early-stage ER+ breast cancer patients compliant with ET each experienced a 2.6% IBTR rate. Spanish/Hispanic/Latinos and Asian/Pacific Islanders had higher IBTR despite better ET compliance, consistent with other published studies.
- letrozole / Generic mfg., anastrozole / Generic mfg.
Endocrine therapy alone in older adults with good prognosis estrogen receptor-positive breast cancer () - Apr 29, 2022 - Abstract #ASBrS2022ASBrS_401;
These are important data to move forward in comparing endocrine therapy to surgical therapy. Limitations of our study would be differences in obtaining the images.
- ||| Kisqali (ribociclib) / Novartis
Enrollment closed, Metastases: RIGHT Choice: Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Apr 28, 2022
P2, N=225, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Limitations of our study would be differences in obtaining the images. Recruiting --> Active, not recruiting
- letrozole / Generic mfg., anastrozole / Generic mfg., tamoxifen / Generic mfg.
Short-term preoperative endocrine therapy allows to estimate and revert patient prognosis with further treatment plan correction in HR+ HER2- early breast cancer patients. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_5949;
HR+ HER2- BC pts stages I-II any level of Ki67 independent from grade have received P-ET (letrozole (L)/anastrozole (A)/tamoxifen (TAM)) no less than 2 weeks until surgery in MCSC named after A.S. Loginov. In HR+ HER2- early BC pts short-term P-ET simply allows to estimate pts prognosis and further AT strategy proper planning: to identify the pts population of whom CT can be avoided while maintaining treatment efficacy with a better quality of life (42% pts of IIT) (1), to radically change the planned AT to achieve optimal treatment results (2,4% pts of IIT) (2).
- Apristor (onapristone XR) / Context Therap
Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC). (Available On Demand; 400) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5465;
P2
No objective responses were observed. Cohorts 1-3 have closed to accrual, with 2 patients continuing active treatment for >18 months.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC). (Available On Demand; 17) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5062;
P1b, P1b/2
The RP2Ds for the T-DXd combinations were the standard doses for BC of each individual drug. These studies are ongoing, with additional T-DXd combinations being evaluated and further follow-up underway.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer. (Available On Demand; 386a) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3320;
P2
To our knowledge this is the first and only ongoing study evaluating T-DXd with or without endocrine therapy for HR+, HER2-low BC in the neoadjuvant setting. The study will shed light on clinical activity and biomarkers, which may guide larger confirmatory studies for this population.
- Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
A phase 3, single arm, open-label study evaluating ovarian suppression following 3-month leuprolide acetate for injectable suspension in combination with endocrine therapy in premenopausal subjects with HR+, HER2-negative breast cancer (OVELIA). (Available On Demand; 378b) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3305;
P3
Achievement of ovarian suppression will be defined as ≥ 90% of subjects with luteinizing hormone (LH) levels < 4 IU/L at Week 6. Secondary endpoints include suppression of LH, E2 (< 20 pg/mL for tamoxifen cohort and < 2.72 pg/mL for AI cohort) and absence of menses at weeks 6, 12, 24, 36, and 48.
- Ibrance (palbociclib) / Pfizer, giredestrant (GDC-9545) / Roche
Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study. (Available On Demand; 360) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3286;
P2
In this final analysis of coopERA BC, the greater suppression of Ki67 with giredestrant vs A observed at Week 2 in the primary analysis was maintained at surgery, and safety data remained consistent with the known safety profile of giredestrant. coopERA BC is the first randomized study to show superior antiproliferative activity of an oral SERD (giredestrant) over an aromatase inhibitor (A) in ER+/HER2– eBC; studies are ongoing to further assess giredestrant’s clinical benefit.
- Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis. (Available On Demand; 307) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3233;
The sequential use of aromatase inhibitors may be the optimal treatment mode for hormone receptor-positive postmenopausal early breast cancer patients. In addition, the three kinds of aromatase inhibitors achieved roughly equal efficacy, but caused different types of SAEs.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
The effect of BMI on the outcomes of CDK 4/6 inhibitor therapy in HR-positive metastatic breast cancer patients. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1232;
In this study, we demonstrated the tendency that overweight patients with metastatic breast cancer may benefit more from CDK4/6 inhibitors in term of PFS from interim analyses of our data. Similar toxicity rates and adverse events were observed in all BMI groups with CDK4/6 inhibitors plus ET.
- dalpiciclib (SHR6390) / Jiangsu Hengrui Medicine
Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR+/HER2- advanced breast cancer: A phase Ib study. (Available On Demand; 444) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1153;
P1/2
The recommended phase 3 dose of dalpiciclib was 150 mg. Together with the promising anti-tumor activity observed with the combination therapy in HR+/HER2- ABC, further trials are warranted.
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Aromatase inhibitors for breast cancer therapy: Analysis of real-world FAERS data. (Available On Demand; 429) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1138;
Together with the promising anti-tumor activity observed with the combination therapy in HR+/HER2- ABC, further trials are warranted. The findings in this study highlight trends for selected AEs with various AI regimens, provide further insights, and help guide therapeutic decisions for patients with HRPBC.
- anastrozole / Generic mfg.
Predictive value of baseline patient-rated treatment bother for early anastrozole discontinuation in a racially diverse cohort: Results from ECOG-ACRIN E1Z11. (Available On Demand; 340) - Apr 28, 2022 - Abstract #ASCO2022ASCO_902;
P=N/A
Our findings support the presence of a treatment tolerability threshold which can be compromised by pre-treatment burden. Treatment tolerability may also be influenced by cultural and genetic factors, which will be explored in further analysis of genetic and PRO data.
- | Reimbursement, Journal, HEOR, Medicare: Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study. (Pubmed Central) - Apr 26, 2022
Treatment tolerability may also be influenced by cultural and genetic factors, which will be explored in further analysis of genetic and PRO data. Although there was no significant difference in physical HRQoL scores between AET agents, anastrozole and tamoxifen were associated with better mental HRQoL scores.
- | Herceptin (trastuzumab) / Roche
Journal: Assessment of Breast Cancer Management in Sub-Saharan Africa. (Pubmed Central) - Apr 22, 2022
Socioeconomic and cultural barriers and system delays persist. Workforce expansion must be prioritized to improve quality of care to improve outcomes.
- | anastrozole / Generic mfg., tamoxifen / Generic mfg.
Biomarker, Journal: Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. (Pubmed Central) - Apr 22, 2022
In postmenopausal ER+/HER2- breast cancer patients, SPRS provided more prognostic information than RS for DR when used alone or in combination with the CTS. The SPRS could therefore potentially identify high-risk patients, who might benefit from aggressive treatments, from low-risk patients who might safely avoid adjuvant chemotherapy or prolongation of endocrine therapy.
- Management of the Side Effect of Hormone Therapy () (RM 3(Walker Hall 1)) - Apr 22, 2022 - Abstract #GBCC2022GBCC_186;
This is crucial to increase treatment adherence and quality of life during adjuvant endocrine therapy. An individualized approach when choosing an intervention to control these symptoms is likely to have better chances of achieving a positive effect on oncological outcomes and quality of life.
- Must-have Knowledge about GnRH Agonist for Patients with Breast Cancer (RM 5(Art Hall)) - Apr 22, 2022 - Abstract #GBCC2022GBCC_164;
In the light of increased morbidity with aromatase inhibitors and in the context of the reported data of the SOFT/TEXT trials, most patients are optimally treated with tamoxifen and ovarian function suppression (OFS). However, the option of aromatase inhibitors and OFS should be discussed on an individual basis.
- || letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Clinical, Journal: Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients. (Pubmed Central) - Apr 21, 2022
We present here an assay suitable for the simultaneous measurement of serum levels of all third-generation AIs and ultra-low levels of estrogens, providing a powerful new tool to study drug efficacy and compliance. The method is highly valuable for postmenopausal patients whose pretreatment estradiol levels are below the threshold of detection for most routine assays, but still require suppression.
- | Trial completion date: Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT) (clinicaltrials.gov) - Apr 21, 2022
P4, N=231, Active, not recruiting, Sponsor: Ottawa Hospital Research Institute
The method is highly valuable for postmenopausal patients whose pretreatment estradiol levels are below the threshold of detection for most routine assays, but still require suppression. Trial completion date: Aug 2024 --> Aug 2022
- || Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Clinical, Retrospective data, Journal: Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. (Pubmed Central) - Apr 20, 2022
Older monotherapies that continue to be used in RCTs in comparator groups, such as anastrozole (251 of 252) and letrozole (252), fell to the bottom of the rankings...In this network meta-analysis study, combination therapies appeared to be associated with better outcomes than monotherapies in the treatment of HR-positive, ERBB2-negative MBC. These findings suggest that IT-NMA is a promising method for longitudinal ranking of anticancer regimens from RCTs with different end points, sparse interconnectivity, and decades-long timeframes.
- | anastrozole / Generic mfg.
غذا باعث کاهش سرعت جذب می شود اما این مورد از لحاظ بالینی مهم نمی باشد. Anastrozole به میزان 40% به پروتئین های پلاسما متصل می شود. در کبد متابولیزه می گردد و از طریق ادرار دفع می شود که عمدتاً به شکل متابولیت ها می باشد. عوارض جانبی @merck #stopanimaltesting (Twitter) - Apr 15, 2022
- || Tasigna (nilotinib) / Novartis, Inhibikase
Clinical, Journal: Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation. (Pubmed Central) - Apr 13, 2022
Co-medication with DOAC and ACDs with inhibitory or competitive effects on CYP3A4 or P-gp activity was not associated with a higher risk of major bleeding than DOAC alone. Our findings may provide clinicians with confidence regarding the safety of concurrent use of DOAC and ACDs in patients with AF and cancer.
- || rodatristat ethyl (RVT-1201) / Sumitomo Dainippon, sotatercept (ACE-011) / BMS, Merck (MSD)
Review, Journal: "NOVEL MECHANISMS TARGETED BY DRUG TRIALS IN PULMONARY ARTERIAL HYPERTENSION". (Pubmed Central) - Apr 13, 2022
In this review, we will discuss the preclinical studies that led to prioritization of these mechanisms and will discuss recently completed and ongoing phase 2/3 trials using novel interventions such as sotatercept, anastrozole, rodatristat ethyl, tyrosine kinase inhibitors, and endothelial progenitor cells among others. We anticipate that the next generation of compounds will build upon the success of the current standard of care and improve clinical outcomes and quality of life of patients afflicted with PAH.